Microfluidic EV Isolation via Chaotic Mixing and Antibody Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating extracellular vesicles (EVs), particularly tumor-derived EVs, face challenges such as low specificity, low throughput, and inefficiency due to reliance on physical properties like ultracentrifugation and antibody-coated bead assays, which often capture non-target EVs and require lengthy processes.
Innovation Solution
A microfluidic system with channels coated with antibodies and herringbone grooves, utilizing elongated flexible linker molecules and nanostructured substrates to selectively capture target EVs, enabling high specificity and rapid isolation of tumor-derived EVs from fluid samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ultracentrifugation and antibody-coated bead assays are used for EV isolation, then EVs can be isolated from fluid samples, but the methods achieve low specificity and capture non-target EVs
Solution Approach 1:
The invention segments the EV isolation process into multiple stages: (1) pre-concentration using microfluidic negative pressure filtration to separate EVs from bulk fluid, (2) selective capture using antibody-coated microbeads that specifically bind to tumor-derived EV markers, and (3) post-processing through size-exclusion chromatography to further purify the isolated EVs. This multi-stage segmentation enables high specificity by addressing each separation challenge individually rather than relying on a single low-specificity method.
Solution Approach 2:
The invention introduces antibody-coated microbeads as intermediary carriers that mediate the specific capture of tumor-derived EVs. The microbeads serve as a bridge between the fluid sample and the target EVs, with antibodies on the bead surface providing selective binding to tumor EV markers. This intermediary approach enables specific capture without directly exposing the target EVs to harsh conditions, thereby maintaining both specificity and reliability.
2Productivity
If conventional EV isolation methods are used, then EVs can be isolated, but the processes require lengthy procedures and low throughput
Solution Approach 1:
The invention replaces traditional mechanical separation methods (ultracentrifugation requiring high-speed rotation and long sedimentation times) with a microfluidic-based system that uses controlled fluid flow, pressure gradients, and chip-based filtration. The microfluidic device processes EVs at rates of milliliters per minute, reducing isolation time from hours to minutes while maintaining high throughput capability.
Solution Approach 2:
The invention transitions from bulk-phase isolation methods to micro-scale processing by confining fluid flow within microfluidic channels with dimensions of micrometers. This dimensional scaling enables rapid mass transfer, enhanced surface-area-to-volume ratios for efficient capture, and precise control over flow dynamics, all of which contribute to faster processing and higher throughput compared to conventional macro-scale methods.
3Measurement precision
If physical properties like size and density are used for EV isolation, then EVs can be separated from fluid, but tumor-derived EVs cannot be distinguished from normal cell EVs
Solution Approach 1:
The invention applies local quality by functionalizing specific regions of the microfluidic system with tumor-specific antibodies only in the capture zone, while other regions maintain different properties for pre-concentration and post-processing. The antibody-coated microbeads are strategically positioned in the microfluidic channel to provide selective binding activity only where needed, enabling distinction between tumor-derived EVs and normal cell EVs based on their unique surface markers rather than generic physical properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high specificity (approximately 94%) and efficient capture of target EVs within 3 hours, allowing for downstream characterization and analysis, and can distinguish between EVs from normal and tumor cells, facilitating their use as disease-specific biomarkers.
Implementation Method 1
The microfluidic device includes a microfluidic channel where an internal surface of at least one wall of the microfluidic channel includes a plurality of grooves or ridges, or both grooves and ridges, arranged and configured to generate chaotic mixing within a fluid sample flowing through the microfluidic channel
Implementation Method 2
a plurality of elongate flexible linker molecules, each having a molecular weight between about 1.8-4.8 kDa, where each elongate flexible linker molecule is bound at a first end to an internal surface of at least one wall of the microfluidic channel
Implementation Method 3
bound at a second end to one or more binding moieties that specifically bind to a target extracellular vesicle
Data Source
AI summary
Systems and techniques are described for capturing target extracellular vesicles from a fluid sample. In some implementations, a microfluidic device includes a microfluidic channel where an internal surface of at least one wall of the microfluidic channel includes a plurality of grooves or ridges, or both grooves and ridges, arranged and configured to generate chaotic mixing within a fluid sample flowing through the microfluidic channel. The microfluidic device also includes a plurality of elongate flexible linker molecules, each having a molecular weight between about 1.8-4.8 kDa, where each elongate flexible linker molecule is bound at a first end to an internal surface of at least one wall of the microfluidic channel and is bound at a second end to one or more binding moieties that specifically bind to a target extracellular vesicle.